|
Patent landscape, scope, and claims: |
Scope and Claims Breakdown of US Patent 12,453,726: Methods Normalizing Intravascular/Extravascular Hemolysis with Oral 4-((2S,4S)-(4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl))benzoic Acid
US Patent 12,453,726 claims a narrow but operationally detailed US method-of-treatment estate for oral dosing (about 200 mg twice daily) of a specific benzoic acid compound (including its hydrochloride salt dosing reference via anhydrous free base), targeted to PNH-associated hemolysis and measured hematology endpoints. The claims are written as “method of normalizing IVH and/or EVH” and separately as “method of treating IVH” and “method of treating EVH,” with multiple dependent claim layers that lock down: (i) minimum hemoglobin rise magnitude, (ii) specific biomarker directionality (haptoglobin/reticulocytes/bilirubin), (iii) LDH reduction for IVH, (iv) transfusion-avoidance and/or “residual anemia” populations, (v) prior anti-C5 (monoclonal antibody) treatment sequencing, and (vi) meningococcal vaccination timing.
Important practical impact: outside the exact dosing regimen and endpoint-defined treatment outcomes, the independent claim still preserves some breadth (any “normalizing” of IVH/EVH via oral dosing of the compound), but the dependent claims tighten design space using numeric thresholds and clinical context (PNH, transfusion avoidance, prior anti-C5, vaccination, sustained Hb increases, Hb target levels).
What patents protect normalizing intravascular and extravascular hemolysis with oral 4-((2S,4S)...)-benzoic acid in the US?
US Patent 12,453,726 is a US method-of-use patent focused on oral treatment effects on hemolysis markers. The claim set is built around one compound identity and a single regimen expression, then layers “success criteria” for hematology readouts.
Independent claims: what the estate actually covers
Claim 1 (core claim):
- Treats “a subject in need” of normalizing IVH and/or EVH
- Orally administers the specified compound or pharmaceutically acceptable salt
- Dose: about 200 mg b.i.d.
- Treating framework: normalization of IVH/EVH (no single required biomarker in the independent claim text, but multiple biomarkers are later claimed in dependent claims)
Claim 6 (IVH-specific independent claim):
- Treats IVH only
- Oral dosing: same compound, about 200 mg b.i.d.
- Includes treatment success defined by increasing hemoglobin by ~2 g/dL or more versus baseline (within the claim language)
Claim 10 (EVH-specific independent claim):
- Treats EVH only
- Oral dosing: same compound, about 200 mg b.i.d.
- Includes Hb rise definition: ~2 g/dL or more versus baseline
How the dependent claims map to clinical proof points
Across the dependent claims, the patent frames efficacy through standard hemolysis panel parameters plus LDH:
- Hb increase magnitude: Claim 2 / Claim 6 / Claim 10 specify ≥ ~2 g/dL (relative to pre-dose baseline).
- Biomarker directionality: Claim 3 links normalization to one or more of:
- ↑ haptoglobin
- ↓ reticulocytes
- ↓ bilirubin
- Percent improvement ranges: Claim 4 (haptoglobin) and Claim 5 (bilirubin/reticulocytes) recite granular percentage increments (10% to 90%).
- IVH biomarker specificity: Claim 8 / Claim 9 add LDH reduction (with multiple minimum percentage reductions from 40% to 95%).
- Transfusion context:
- Claim 7 / Claim 22 / Claim 34 / Claim 46 claim Hb rise in absence of receiving one or more RBC transfusions
- Claim 23 / Claim 35 / Claim 47 claim scenarios where the subject has received RBC transfusions
- Population qualifiers:
- Prior anti-C5 therapy: Claim 14-15, Claim 26-27, Claim 38-39
- Residual anemia: Claim 16, Claim 28, Claim 40
- Prior vaccination against Neisseria meningitidis (A, C, Y, W-135): Claim 24, Claim 36, Claim 48
- PNH associated hemolysis: Claim 19 and Claim 31
- “Sustained increase in hemoglobin level” and target thresholds: Claim 20-21, Claim 32-33, Claim 44-45
Claim “identity and regimen” choke points
The estate is anchored to a very specific compound naming structure and dosing expression:
- Oral dosing of 4-((2S,4S)-(4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl))benzoic acid) or salt
- Dose: about 200 mg b.i.d.
- Dosing amount reference: “refers to the anhydrous free base of … hydrochloride” (a salt/free-base conversion instruction that matters for generic or bioequivalence design)
How many US “patent points” are created by this claim architecture?
Even without enumerating other patents in the family, the internal layers create multiple, legally distinct “claim targets” that could support:
- infringement theories against product labels and clinical protocols,
- combination-therapy sequencing infringement (anti-C5 prior treatment),
- and population-selection infringement (residual anemia, transfusion context, vaccination status).
What is the claim scope for US Patent 12,453,726: method steps, patient selection, and endpoints?
Method-of-treatment steps
The claims are primarily “administer the drug” claims with embedded efficacy definitions:
- Select a subject in need of normalization of IVH/EVH, or a subject to be treated for IVH/EVH.
- Administer orally the specified compound or acceptable salt.
- Dose at about 200 mg twice daily.
- Achieve specified efficacy endpoints, where recited:
- Hb rise ≥ 2 g/dL (independent claims 6 and 10, and also embedded in claim 1’s normalization context)
- Optional/dependent biomarker outcomes (haptoglobin, reticulocytes, bilirubin, LDH)
- Optional/transfusion avoidance conditions
- Optional/dependent sustained Hb increase thresholds
- Optional/dependent anti-C5 prior treatment and vaccination status
Endpoint definitions and threshold locking
Key “success criteria” likely to be central in enforcement:
- Hemoglobin:
- at least about 2 g/dL rise vs baseline (claims 2, 6, 10)
- to ≥ about 12 g/dL (claims 21, 33, 45)
- sustained Hb increase (claims 20, 32, 44)
- Haptoglobin:
- increased by specified percentage ranges from 10% up to 90% (claim 4)
- Reticulocytes / bilirubin:
- reduced by specified percentage ranges from 10% up to 90% (claim 5 and claim 13)
- LDH (IVH only):
- reduced by specified minimum percentages from 40% to 95% (claims 9 and 9’s dependency)
Treatment-context limitations that narrow design space
- Transfusion avoidance: “in the absence of receiving RBC transfusions” (claims 7, 22, 34, 46)
- Anti-C5 prior therapy:
- claim language requires subject “previously treated” with anti-C5; and anti-C5 is specified as monoclonal antibody in multiple places (claims 14-15, 26-27, 38-39)
- Vaccination requirement:
- subject vaccinated against Neisseria meningitidis (types A, C, Y and W-135) prior to administration (claims 24, 36, 48)
- PNH:
- explicit “PNH associated hemolysis” (claims 19 and 31)
How claim drafting affects enforceability
Because the independent IVH/EVH claims embed quantified Hb increases and because dependent claims embed additional quantitative biomarker changes, enforcement can be staged:
- “core infringement” based on oral administration at about 200 mg b.i.d. with measured Hb outcomes, and
- “hardening” based on additional restricted cohorts and biomarker results tied to clinical trial endpoints or label language.
How strong is the patent estate for methods normalizing IVH/EVH: breadth vs. design-around risk?
This is a narrow compound-regimen-and-outcome method estate. Strength hinges on whether competitors’ programs:
- stay outside “about 200 mg b.i.d.”,
- avoid meeting the endpoint thresholds in practice,
- or avoid the constrained contexts (PNH, transfusion avoidance, anti-C5 sequencing, vaccination status).
Breadth drivers
- Independent claim 1 covers “IVH and/or EVH” normalization via oral dosing of the specified compound/salt.
- Claim 1 does not require a specific biomarker in its text (dependent claims add biomarker constraints).
Breadth limiters
- The dose is repeatedly specified as about 200 mg b.i.d.
- Claim 6 and 10 explicitly require Hb increase by about 2 g/dL or more.
- Claim 8-9 add LDH reductions for IVH.
- Population and context qualifiers narrow the clinical scenarios where infringement arguments become strongest:
- PNH associated hemolysis
- prior anti-C5 monoclonal antibody therapy
- prior meningococcal vaccination
- residual anemia
Design-around pathways implied by the claims
- Dose shifting: changing from the claimed “about 200 mg b.i.d.” regimen could reduce risk, but “about” still leaves room and would become fact-dependent.
- Different endpoints framing: a competitor could argue their protocol does not target or achieve “about 2 g/dL” rise or dependent biomarker thresholds.
- Avoiding constrained subpopulations: if a competitor’s label excludes PNH, excludes transfusion-avoidance positioning, or changes sequencing relative to anti-C5 and vaccination expectations, the most direct dependent claim pathways may weaken.
When does US Patent 12,453,726 lose exclusivity in the US? What expiration does the claim set support?
No data is provided here for:
- filing date,
- priority date,
- patent term adjustment (PTA),
- or terminal disclaimers,
so a reliable exclusivity/expiration timeline cannot be computed from the claim text alone.
What is the Orange Book status of the compound in US Patent 12,453,726?
No Orange Book listing, NDA/BLA number, application holder, or US product identity is provided in the prompt. Patent claim text alone is insufficient to establish the Orange Book status or listing type (drug substance vs product, method-of-use vs formulation, etc.).
Which Paragraph IV challenges target US Patent 12,453,726 and how do they affect generic entry risk?
No ANDA/BLA, no US generic applicant names, and no Paragraph IV notice or litigation docket information is included. Without that, the Paragraph IV landscape cannot be mapped.
What patent litigation affects infringement risk under US Patent 12,453,726?
No litigation or settlement details (case captions, districts, docket numbers, or parties) are provided. The claim set alone cannot be tied to an asserted-claim record.
How does US Patent 12,453,726 compare with other hemolysis normalization patents for PNH (method-of-use breadth and biomarkers)?
Within the provided claim text, US Patent 12,453,726 is differentiated by:
- oral dosing with a specific benzoic acid compound,
- dual coverage of IVH and EVH in one estate (independent claim 1 plus separate IVH and EVH independents),
- explicit Hb success thresholds,
- and addition of LDH reduction for IVH plus transfusion-avoidance and vaccination/anti-C5 sequencing dependent layers.
A cross-patent comparison to “other hemolysis normalization patents” requires other patent numbers or a list of family members, which is not provided.
What formulations or salt forms are covered by US Patent 12,453,726 (hydrochloride dosing vs free base)?
The claims cover:
- orally administering the compound or “a pharmaceutically acceptable salt”
- with dosing amount referring to the anhydrous free base of the hydrochloride salt.
This matters for any generic or salt-formulation strategy:
- even if a competitor uses a different salt form, infringement risk would still be evaluated under “pharmaceutically acceptable salt” coverage and whether the dosing converts to the claimed anhydrous free-base amount at “about 200 mg b.i.d.”
What generic entry risks exist for oral hemolysis normalization dosing around 200 mg twice daily?
Risk categories implied by the claim language:
- Direct-label replication risk: if a generic or follow-on product’s proposed label or protocol includes oral administration at about 200 mg b.i.d. for IVH/EVH normalization in the specified patient contexts, risk increases.
- Endpoint-driven risk: even if a competitor changes messaging, clinical practice that produces the claimed Hb and biomarker outcomes could still fall within claim scope for infringement theories requiring achieving those results.
- Context-driven risk: risk rises if competitor studies or real-world use include:
- PNH-associated hemolysis,
- anti-C5 monoclonal antibody prior therapy,
- residual anemia populations,
- and meningococcal vaccination timing.
Key Takeaways
- US Patent 12,453,726 is a method-of-treatment estate for oral dosing at about 200 mg b.i.d. of a specific benzoic acid compound aimed at normalizing IVH and/or EVH, with independent claims anchored to Hb increases and separate IVH/EVH framing.
- The dependent claims add enforceable layers: quantitative biomarker changes (Hb, haptoglobin, reticulocytes, bilirubin, LDH), transfusion avoidance, sustained Hb targets, and tightly defined patient context (PNH, prior anti-C5 monoclonal antibody therapy, residual anemia, and prior meningococcal vaccination).
- The claims are operationally narrow enough to create design-around opportunities via dose shifting and endpoint or population selection, but the “about” dosing language and outcome-linked claim language can make real-world performance a central enforcement variable.
FAQs
-
Does US Patent 12,453,726 require demonstrating haptoglobin or bilirubin changes for infringement?
Independent claims define normalization/treatment and, for claims 6 and 10, embed Hb increase thresholds; haptoglobin/bilirubin/reticulocyte and percent-change limitations are in dependent claims.
-
Is LDH reduction required for treating IVH under US Patent 12,453,726?
It appears in a dependent IVH pathway (claim 8-9). The independent IVH claim is structured around Hb increase.
-
Can a treatment be infringing if the patient received RBC transfusions?
The patent includes dependent claims for both transfusion-avoidance and transfused scenarios, so transfusion status is part of the claim landscape.
-
How does prior anti-C5 monoclonal antibody treatment affect the claim scope?
Multiple dependent claims require the subject was previously treated with anti-C5 therapy, with monoclonal antibody specified in those dependents.
-
Is vaccination against Neisseria meningitidis a required condition?
Vaccination timing is required in dependent claims, not in the broadest independent claim set.
References
No sources are provided in the prompt for: the patent record (USPTO), prosecution history, patent term calculations, Orange Book listings, litigation dockets, or ANDA notice records. Therefore, no APA citations can be generated from the information given.
More… ↓
⤷ Start Trial
|
